Asked by: Gregory Campbell (Democratic Unionist Party - East Londonderry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the effectiveness of the help us, help you campaign.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
No recent assessment has been made. In 2020 NHS England launched the Help Us, Help You (HUHY) campaigns, a major public information campaign to persuade the public to seek urgent care and treatment when they needed it. The HUHY campaign strategy is designed to address the underlying barriers to cancer diagnosis, including multifaceted fears and a lack of body vigilance, along with the lack of knowledge of cancer symptoms, to encourage people to present earlier.
On 8 January 2024, NHS England relaunched the HUHY campaign for cancer, designed to increase earlier diagnosis of cancer by reducing barriers to seeking earlier help, as well as increasing body vigilance and knowledge of key red flag symptoms. This campaign addresses barriers to people coming forward with suspected signs of cancer in general, and is not specific to screening or cervical cancer.
We are seeing continued high levels of urgent cancer referrals, which suggests the HUHY campaigns continue to be effective. Over 12,000 urgent referrals were seen for suspected cancer per working day in February 2024, compared to approximately 9,000 in January 2020.
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to NICE guidance entitled Integrated health and social care for people experiencing homelessness, published on 16 March 2022, what steps her Department is taking to ensure that people experiencing homelessness have somewhere safe and secure to recover when discharged from hospital.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The Department is committed to promoting safe and timely discharge for people experiencing, or at risk of, homelessness, to appropriate accommodation.
We have ensured every acute hospital has access to a care transfer hub to manage discharge for people with more complex needs. In January 2024, the Department published guidance on discharging people at risk of or experiencing homelessness, to support staff involved in planning safe and supportive discharge of these patients from hospital. The guidance is available at the following link:
Asked by: Karin Smyth (Labour - Bristol South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of capacity in district nursing on the timeliness of patient discharge from hospital in 2023.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure that (a) young and (b) vulnerable people have access to free contraception.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Emily Thornberry (Labour - Islington South and Finsbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the contract awarded by her Department to Ethypharm UK Ltd on 27 January 2022 for the storage and management of the Department's Naloxone buffer stock, how many packs of Naloxone were distributed from the buffer stock for use by patients in the UK in the (a) 2021-22, (b) 2022-23, and (c) 2023-24 financial year.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Karin Smyth (Labour - Bristol South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many emergency hospital admissions there have been following falls by patients aged 65 and over in each financial year since 2010-11.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
NHS England publishes information on finished consultant episodes (FCEs) for admitted patients, which is available at the following link:
The following table shows the total number of FCEs relating to a fall, where the patient was 65 years old or over, each year from 2012/13, the earliest year from which data is available, to 2022/23:
Year | FCEs relating to a fall |
2012/13 | 283,794 |
2013/14 | 290,381 |
2014/15 | 304,049 |
2015/16 | 312,476 |
2016/17 | 316,647 |
2017/18 | 334,986 |
2018/19 | 345,494 |
2019/20 | 360,677 |
2020/21 | 334,418 |
2021/22 | 350,545 |
2022/23 | 339,928 |
Asked by: Karin Smyth (Labour - Bristol South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many care contacts were carried out by district nurses in each of the last 10 years.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The Department does not hold this information.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to recent research conducted by the Lancet Commission, what steps they plan to take to address the projected surge in prostate cancer cases.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, what plans they have to use artificial intelligence systems to support the diagnosis of prostate cancer, as recommended by the Lancet Commission in research published on 4 April.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she plans to take to ensure that online pharmacies that provide medicines to patients in the UK adhere to the NHS clinical guideline on puberty-suppressing hormones or the treatment of children and adolescents who have gender (a) incongruence and (b) dysphoria.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
All community pharmacists, whether working on a high street or online, have a duty of care to their patients. We would expect pharmacists to take reasonable steps to ensure that all the medicines they dispense are against legally valid prescriptions, and appropriate for the patient under the authority of the prescriber. This includes both National Health Service prescriptions and private prescriptions. Registered pharmacy professionals and premises are independently regulated by the General Pharmaceutical Council (GPhC), and guidance has been issued for those providing services at a distance, including online pharmacies.
While pharmacists are responsible for a final clinical check, ultimately the responsibility for the product prescribed rests with the prescriber. We are looking closely at what can be done to address any loopholes in prescribing practices, including work with the GPhC to define the dispensing responsibilities of pharmacists providing private prescriptions, as recommended by the Cass Report.